Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat

被引:105
|
作者
Iemitsu, M
Miyauchi, T [1 ]
Maeda, S
Sakai, S
Kobayashi, T
Fujii, N
Miyazaki, H
Matsuda, M
Yamaguchi, I
机构
[1] Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Cardiovasc, Tsukuba, Ibaraki 3050006, Japan
[2] Univ Tsukuba, Inst Appl Biochem, Gene Expt Ctr, Tsukuba, Ibaraki 3050006, Japan
[3] Univ Tsukuba, Inst Hlth & Sport Sci, Tsukuba, Ibaraki 3050006, Japan
关键词
cardiovascular regulating factor; athletic heart; spontaneously hypertensive rat; swim training; hypertension;
D O I
10.1152/ajpregu.2001.281.6.R2029
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Pressure overload, such as hypertension, to the heart causes pathological cardiac hypertrophy, whereas chronic exercise causes physiological cardiac hypertrophy, which is defined as athletic heart. There are differences in cardiac properties between these two types of hypertrophy. We investigated whether mRNA expression of various cardiovascular regulating factors differs in rat hearts that are physiologically and pathologically hypertrophied, because we hypothesized that these two types of cardiac hypertrophy induce different molecular phenotypes. We used the spontaneously hypertensive rat (SHR group; 19 wk old) as a model of pathological hypertrophy and swim-trained rats (trained group; 19 wk old, swim training for 15 wk) as a model of physiological hypertrophy. We also used sedentary Wistar-Kyoto rats as the control group (19 wk old). Left ventricular mass index for body weight was significantly higher in SHR and trained groups than in the control group. Expression of brain natriuretic peptide, angiotensin-converting enzyme, and endothelin-1 mRNA in the heart was significantly higher in the SHR group than in control and trained groups. Expression of adrenomedullin mRNA in the heart was significantly lower in the trained group than in control and SHR groups. Expression of beta (1)-adrenergic receptor mRNA in the heart was significantly higher in SHR and trained groups than in the control group. Expression of beta (1)-adrenergic receptor kinase mRNA, which inhibits beta (1)-adrenergic receptor activity, in the heart was markedly higher in the SHR group than in control and trained groups. We demonstrated for the first time that the manner of mRNA expression of various cardiovascular regulating factors in the heart differs between physiological and pathological cardiac hypertrophy.
引用
收藏
页码:R2029 / R2036
页数:8
相关论文
共 50 条
  • [1] Physiological and pathological cardiac hypertrophy
    Shimizu, Ippei
    Minamino, Tohru
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2016, 97 : 245 - 262
  • [2] Mechanisms of physiological and pathological cardiac hypertrophy
    Michinari Nakamura
    Junichi Sadoshima
    [J]. Nature Reviews Cardiology, 2018, 15 : 387 - 407
  • [3] Mechanisms of physiological and pathological cardiac hypertrophy
    Nakamura, Michinari
    Sadoshima, Junichi
    [J]. NATURE REVIEWS CARDIOLOGY, 2018, 15 (07) : 387 - 407
  • [4] Phenylephrine, endothelin, prostaglandin F2α, and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro, and leukemia inhibitory factor induce different cardiac hypertrophy phenotypes in vitro
    Kathleen L. King
    Jane Winer
    David M. Phillips
    James Quach
    P. Mickey Williams
    Jennie P. Mather
    [J]. Endocrine, 1998, 9 : 45 - 55
  • [5] Endurance Training in the Spontaneously Hypertensive Rat Conversion of Pathological into Physiological Cardiac Hypertrophy
    Garciarena, Carolina D.
    Pinilla, Oscar A.
    Nolly, Mariela B.
    Laguens, Ruben P.
    Escudero, Eduardo M.
    Cingolani, Horacio E.
    Ennis, Irene L.
    [J]. HYPERTENSION, 2009, 53 (04) : 708 - U229
  • [6] Resveratrol prevents pathological but not physiological cardiac hypertrophy
    Vernon W. Dolinsky
    Carrie-Lynn M. Soltys
    Kyle J. Rogan
    Anita Y. M. Chan
    Jeevan Nagendran
    Shaohua Wang
    Jason R. B. Dyck
    [J]. Journal of Molecular Medicine, 2015, 93 : 413 - 425
  • [7] Resveratrol prevents pathological but not physiological cardiac hypertrophy
    Dolinsky, Vernon W.
    Soltys, Carrie-Lynn M.
    Rogan, Kyle J.
    Chan, Anita Y. M.
    Nagendran, Jeevan
    Wang, Shaohua
    Dyck, Jason R. B.
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2015, 93 (04): : 413 - 425
  • [8] Pathological vs. physiological cardiac hypertrophy
    Kavazis, Andreas N.
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2015, 593 (17): : 3767 - 3767
  • [9] Transcriptional profiles in physiological and pathological cardiac hypertrophy
    Rodrigo, MC
    Collier, M
    Uezato, H
    Deng, D
    Bristow, J
    Simpson, PC
    [J]. CIRCULATION, 2002, 106 (19) : 34 - 34
  • [10] Different roles of BAG3 in cardiac physiological hypertrophy and pathological remodeling
    Jia, Pengyu
    Wu, Nan
    Yang, Huimin
    Guo, Yuxuan
    Guo, Xiaofan
    Sun, Yingxian
    [J]. TRANSLATIONAL RESEARCH, 2021, 233 : 47 - 61